EMAIL THIS PAGE TO A FRIEND

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology

Vaginal atrophy in breast cancer survivors: role of vaginal estrogen therapy.


PMID 22994445

Abstract

Early menopause and related vaginal atrophy is a well known side-effect of hormone adjuvant treatment in breast cancer patients, particularly during aromatase-inhibitors therapy. Due to estrogens contra-indication, proper therapy for such symptom remains often an inadequately addressed clinical problem. After an accurate assessment of the risk/benefit ratio, vaginal low-dose estrogen treatment (better with estriol) [corrected] may have a role in controlling vaginal atrophy in selected and informed breast cancer women.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

E3750
17-Epiestriol
C18H24O3